This is an unofficial archive of PsychonautWiki as of 2025-08-08T03:33:20Z. Content on this page may be outdated, incomplete, or inaccurate. Please refer to the original page for the most up-to-date information.
Talk:2-Methyl-AP-237
From PsychonautWiki Archive
Revision as of 22:07, 7 April 2024 by >Kroko(Fixed)
WARNING: Always start with lower doses due to differences between individual body weight, tolerance, metabolism, and personal sensitivity. See responsible use section.
DISCLAIMER: PW's dosage information is gathered from users and resources for educational purposes only. It is not a recommendation and should be verified with other sources for accuracy.
This article is in the 'Talk' namespace because it is an unfinished draft. This section is used to host drafts for unpublished articles as well as discussions for published ones. If you'd like to use this area to discuss this draft, please do so in the 'Discussion' section at the very bottom of the page. This notice will be removed once this draft has been approved for publication by an administrator.
As a result, it may contain incomplete or wrong information. You can help by expanding it.
2-methyl AP 237 is a research chemical opioid, Little is known about this chemical as was first identified by a police forensic laboratory in Slovenia in March 2019. Page text.[2]
Studies have shown bucinnazine and similar acyl piperazines, substances close to 2 MAP to be potent and selective agonists of μ-opioid receptor and they are thought to raise tolerance quickly
2-Methyl AP 237 is an agonist of Mu opioid receptor with potency about equal to morphine
2-Methyl AP-237 was found to bind to MOR with appreciable affinity (Ki = 12.9 nM) and high
selectivity over the δ (Ki = 2910 nM) and κ subtypes (Ki = 5259 nM)
|NameCommon=2-Methyl-AP-237, Apex, 2-MAP
Chemical Abstracts Service index name:
1-Butanone, 1-[2-methyl-4-(3-phenyl-2-propen-1-yl)-1-piperazinyl]-
|NameSubstitution=2-Methyl-AP-237
|NameSystematic=1-[2-methyl-4-(3-phenyl-2-propen-1-yl)-1-piperazinyl]-1-butanone, 1-(4-cinnamyl-2-methylpiperazin-1-yl)butan-1-one
Disclaimer: The effects listed below cite the Subjective Effect Index (SEI), an open research literature based on anecdotal user reports and the personal analyses of PsychonautWikicontributors. As a result, they should be viewed with a healthy degree of skepticism.
It is also worth noting that these effects will not necessarily occur in a predictable or reliable manner, although higher doses are more liable to induce the full spectrum of effects. Likewise, adverse effects become increasingly likely with higher doses and may include addiction, severe injury, or death ☠.
Physical effects
If applicable, a brief paragraph summary of the substance's physical effects may be included here.
You may select physical effects to add below here.
Sedation It provide less sedation than opioids like fentanyl but is considerably more sedating than Kratom
Euphoria - This can be described as a powerful and overwhelming feeling of emotional bliss, contentment, and happiness.It is less euphoric than oxycodone or heroin but more than light opioids like codeine.
Double vision - At high doses, opioids can cause the eyes un-focus and re-focus uncontrollably. This creates a blurred effect and double vision that is present no matter where one focuses their eyes.
Hallucinatory states
Internal hallucinations - One may experience feelings of hypnagogia during a state of "nodding" which is often accompanied by vivid dream-like visions.
Tolerance and addiction
The short-term non-chronic use of opioids is not associated with any physical or neurological toxicity.
The long-term use of opioids causes hormonal imbalance in both men and women. In men, this opioid-induced androgen deficiency results in abnormally low levels of sex hormones, particularly testosterone.
This negative change in endocrine function in males can lead to: reduced libido, erectile dysfunction, fatigue, depression, reduced facial and body hair, decreased muscle mass, and weight gain.
Another often observed long-term effect is hyperalgesia, an increase in the pain sensitivity of the person. This is specially seen in chronic pain patients on high dose opioid regimes. There is some evidence that NMDA antagonists like ketamine and opoids that are also weak NMDA antagonist such as methadone, levorphanol and tramadol may help delay the onset of hyperalgesia or even revert it. Nitric synthase inhibitor, COx2 antagonist and alpha 2 agonist can also help.
It is strongly recommended that one use harm reduction practices when using this class of substances.
Due to the highly euphoric nature of these substances, the recreational use and abuse of opioids has an extremely high rate of addiction and dependence. This is combined with a tolerance which builds up quickly, necessitates that the user take increasingly high dosages in order to get the same effects.
}}
Experience reports
There are currently 0 experience reports which describe the effects of this substance in our experience index.
WARNING: Always start with lower doses due to differences between individual body weight, tolerance, metabolism, and personal sensitivity. See responsible use section.
DISCLAIMER: PW's dosage information is gathered from users and resources for educational purposes only. It is not a recommendation and should be verified with other sources for accuracy.
